Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

NCT04702009 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Advanced Lung Carcinoma
Non-small Cell Lung Cancer

Interventions

DRUG: Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy
PROCEDURE: Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China